Pfizer buys Anacor for $5.2bn

Pfizer has announced that it will be buying Anacor Pharmaceuticals for $5.2 billion, which will lead to it adding an experimental treatment for eczema, called Crisaborole, to its portfolio.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Actavis and Pfizer settle Celebrex litigation

29 April 2014 Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

Americas

Flatwing fails to shift attorney fees to Pfizer unit, Anacor

29 June 2021 Generic drug maker Flatwing Pharmaceuticals has lost its bid to offset nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals after a US federal judge ruled that the “circumstances were not exceptional” enough to warrant the shift.

More on this story

Americas

Actavis and Pfizer settle Celebrex litigation

29 April 2014 Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

Americas

Flatwing fails to shift attorney fees to Pfizer unit, Anacor

More on this story

Americas

Actavis and Pfizer settle Celebrex litigation

29 April 2014 Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

Americas

Flatwing fails to shift attorney fees to Pfizer unit, Anacor